脆性 X 综合征：治疗方法的研究进展。
Fragile X syndrome: an update on developing treatment modalities.
机构信息
Seaside Therapeutics, 840 Memorial Drive, Cambridge, Masssachusetts 02139, USA.
出版信息
ACS Chem Neurosci. 2011 Aug 17;2(8):402-10. doi: 10.1021/cn200019z. Epub 2011 Mar 22.
Abstract
Intellectual disability (ID; mental retardation) is considered an immutable condition. Current medical practices are aimed at relieving symptoms and not at altering the underlying cognitive deficits. Scientific advancements from the past decade have led to the exciting possibility that ID may now be treatable. Moreover, pharmaceutical therapies targeting the most common form of inherited ID, Fragile X syndrome (FXS), may become the new benchmark for central nervous system (CNS) drug discovery: seeking cures for neurodevelopmental disorders.
摘要
智力残疾（ID；智力迟钝）被认为是一种不可改变的状况。目前的医疗实践旨在缓解症状，而不是改变潜在的认知缺陷。过去十年的科学进步带来了一个令人兴奋的可能性，即 ID 现在可能是可治疗的。此外，针对最常见的遗传性 ID 形式——脆性 X 综合征（FXS）的药物疗法可能成为中枢神经系统（CNS）药物发现的新基准：寻找神经发育障碍的治疗方法。
相似文献
1
Fragile X syndrome: an update on developing treatment modalities.
ACS Chem Neurosci. 2011 Aug 17;2(8):402-10. doi: 10.1021/cn200019z. Epub 2011 Mar 22.
2
Recent progress on the identification of metabotropic glutamate 4 receptor ligands and their potential utility as CNS therapeutics.
ACS Chem Neurosci. 2011 Aug 17;2(8):433-49. doi: 10.1021/cn200043e. Epub 2011 Jun 14.
3
Fragile X syndrome and targeted treatment trials.
Results Probl Cell Differ. 2012;54:297-335. doi: 10.1007/978-3-642-21649-7_17.
4
Potential therapeutic interventions for fragile X syndrome.
Trends Mol Med. 2010 Nov;16(11):516-27. doi: 10.1016/j.molmed.2010.08.005. Epub 2010 Sep 21.
5
Therapeutic strategies in fragile X syndrome: dysregulated mGluR signaling and beyond.
Neuropsychopharmacology. 2012 Jan;37(1):178-95. doi: 10.1038/npp.2011.137. Epub 2011 Jul 27.
6
[From intellectual disability to new treatment modalities of fragile X syndrome].
Ugeskr Laeger. 2014 Feb 24;176(9A):V06130350.
7
Subchronic administration and combination metabotropic glutamate and GABAB receptor drug therapy in fragile X syndrome.
J Pharmacol Exp Ther. 2011 Sep;338(3):897-905. doi: 10.1124/jpet.111.183327. Epub 2011 Jun 2.
8
R-Baclofen Reverses a Social Behavior Deficit and Elevated Protein Synthesis in a Mouse Model of Fragile X Syndrome.
Int J Neuropsychopharmacol. 2015 Mar 28;18(9):pyv034. doi: 10.1093/ijnp/pyv034.
9
Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP.
Neuropharmacology. 2005 Dec;49(7):1053-66. doi: 10.1016/j.neuropharm.2005.06.004. Epub 2005 Jul 27.
10
Mechanism-based approaches to treating fragile X.
Pharmacol Ther. 2010 Jul;127(1):78-93. doi: 10.1016/j.pharmthera.2010.02.008. Epub 2010 Mar 18.
引用本文的文献
1
Understanding the Molecular Basis of Fragile X Syndrome Using Differentiated Mesenchymal Stem Cells.
Iran J Child Neurol. 2022 Winter;16(1):85-95. doi: 10.22037/ijcn.v15i4.22070. Epub 2022 Jan 1.
2
New Targeted Treatments for Fragile X Syndrome.
Curr Pediatr Rev. 2019;15(4):251-258. doi: 10.2174/1573396315666190625110748.
3
GABA-B Agonist Baclofen Normalizes Auditory-Evoked Neural Oscillations and Behavioral Deficits in the Knockout Mouse Model of Fragile X Syndrome.
eNeuro. 2017 Mar 1;4(1). doi: 10.1523/ENEURO.0380-16.2017. eCollection 2017 Jan-Feb.
4
Drug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric Disorders.
Schizophr Res Treatment. 2016;2016:6378137. doi: 10.1155/2016/6378137. Epub 2016 Mar 17.
5
Inhibition of Group I Metabotropic Glutamate Receptors Reverses Autistic-Like Phenotypes Caused by Deficiency of the Translation Repressor eIF4E Binding Protein 2.
J Neurosci. 2015 Aug 5;35(31):11125-32. doi: 10.1523/JNEUROSCI.4615-14.2015.
6
Epigenetic findings in autism: new perspectives for therapy.
Int J Environ Res Public Health. 2013 Sep 11;10(9):4261-73. doi: 10.3390/ijerph10094261.
7
Rescue of dendritic spine phenotype in Fmr1 KO mice with the mGluR5 antagonist AFQ056/Mavoglurant.
Psychopharmacology (Berl). 2014 Mar;231(6):1227-35. doi: 10.1007/s00213-012-2947-y. Epub 2012 Dec 21.
8
ACS chemical neuroscience molecule spotlight on STX209 (arbaclofen).
ACS Chem Neurosci. 2011 Aug 17;2(8):381. doi: 10.1021/cn200061g. Epub 2011 Jul 6.
9
Development of novel M1 antagonist scaffolds through the continued optimization of the MLPCN probe ML012.
Bioorg Med Chem Lett. 2012 Aug 1;22(15):5035-40. doi: 10.1016/j.bmcl.2012.06.018. Epub 2012 Jun 15.
10
Development of a more highly selective M(1) antagonist from the continued optimization of the MLPCN Probe ML012.
Bioorg Med Chem Lett. 2012 Jan 15;22(2):1044-8. doi: 10.1016/j.bmcl.2011.11.110. Epub 2011 Dec 6.
本文引用的文献
1
A PEDIGREE OF MENTAL DEFECT SHOWING SEX-LINKAGE.
J Neurol Psychiatry. 1943 Jul;6(3-4):154-7. doi: 10.1136/jnnp.6.3-4.154.
2
Pharmacologic rescue of impaired cognitive flexibility, social deficits, increased aggression, and seizure susceptibility in oxytocin receptor null mice: a neurobehavioral model of autism.
Biol Psychiatry. 2011 May 1;69(9):875-82. doi: 10.1016/j.biopsych.2010.12.022. Epub 2011 Feb 21.
3
Cognitive dysfunction and prefrontal synaptic abnormalities in a mouse model of fragile X syndrome.
Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2587-92. doi: 10.1073/pnas.1013855108. Epub 2011 Jan 24.
4
A mouse model of the fragile X premutation: effects on behavior, dendrite morphology, and regional rates of cerebral protein synthesis.
Neurobiol Dis. 2011 Apr;42(1):85-98. doi: 10.1016/j.nbd.2011.01.008. Epub 2011 Jan 8.
5
Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056.
Sci Transl Med. 2011 Jan 5;3(64):64ra1. doi: 10.1126/scitranslmed.3001708.
6
Fragile X mice: reduced long-term potentiation and N-Methyl-D-Aspartate receptor-mediated neurotransmission in dentate gyrus.
J Neurosci Res. 2011 Feb;89(2):176-82. doi: 10.1002/jnr.22546. Epub 2010 Dec 8.
7
Hypersensitivity to mGluR5 and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome.
J Neurosci. 2010 Nov 17;30(46):15616-27. doi: 10.1523/JNEUROSCI.3888-10.2010.
8
Open-label riluzole in fragile X syndrome.
Brain Res. 2011 Mar 22;1380:264-70. doi: 10.1016/j.brainres.2010.10.108. Epub 2010 Nov 5.
9
Self-injurious behavior and fragile X syndrome: findings from the national fragile X survey.
Am J Intellect Dev Disabil. 2010 Nov;115(6):473-81. doi: 10.1352/1944-7558-115.6.473.
10
Open-label add-on treatment trial of minocycline in fragile X syndrome.
BMC Neurol. 2010 Oct 11;10:91. doi: 10.1186/1471-2377-10-91.
Zotero 插件